Find drug development pipeline and deal Updates information

Lead Product(s): Adalimumab

Therapeutic Area: Immunology

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Samsung Bioepis

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership January 16, 2020

Details:

The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).